Long-term safety and tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: A multicenter, randomized, double-blind, placebo-controlled, 48-week extension study

Clinical Therapeutics

Volumn 27, Issue 2, 2005, Pages 174-184

  Masana, Luis ^a   Mata, Pedro ^b   Gagné, Claude ^c   Sirah, Waheeda ^d   Cho, Meehyung ^d   Johnson Levonas, Amy O ^d   Meehan, Alan ^d   Troxell, John K ^d   Gumbiner, Barry ^d  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c LAVAL UNIVERSITY   (Canada)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Coadministration; Ezetimibe; Hypercholesterolemia; Low density lipoprotein cholesterol; Safety; Simvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 16244402675     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.02.011     Document Type: Article

References (13)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
2. van Heek M., France C.F., and Compton D.S. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461 J Pharmacol Exp Ther 283 1997 157 163
3. van Heek M., Farley C., and Compton D.S. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663 Br J Pharmacol 129 2000 1748 1754
4. Knopp R.H., Gitter H., Truitt T. Ezetimibe Study Group Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia Eur Heart J 24 2003 729 741
5. Gagné C., Bays H.E., Weiss S.R. Ezetimibe Study Group Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia Am J Cardiol 90 2002 1084 1091
6. [published correction appears in Am J Cardiol. 1998;82:128] Jones P., Kafonek S., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) Am J Cardiol 81 1998 582 587
7. Knopp R.H. Drug treatment of lipid disorders N Engl J Med 341 1999 498 511
8. Tolman K.G. Defining patient risks from expanded preventive therapies Am J Cardiol 85 2000 15E 19E
9. Davidson M.H., Dillon M.A., and Gordon B. Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects Arch Intern Med 159 1999 1893 1900
10. Farmer J.A., and Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors Drug Saf 23 2000 197 213
11. Ucar M., Mjörndal T., and Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity Drug Saf 22 2000 441 457
12. Ridker P.M., Rifai N., and Rose L. Comparison of Creactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
13. Pearson T.A., Mensah G.A., and Alexander R.W. Centers for Disease Control and Prevention; American Heart Association Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511